DA-2811-C

Dong-A ST Co., Ltd. · Phase 2 active Small molecule

DA-2811-C is a small molecule inhibitor targeting a specific cellular pathway involved in disease pathogenesis.

At a glance

Generic name	DA-2811-C
Sponsor	Dong-A ST Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Mechanism of action

Limited public information is available on the precise molecular mechanism of DA-2811-C. As a Phase 2 investigational drug from Dong-A ST Co., Ltd., detailed mechanistic data may not yet be fully disclosed in the public domain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DA-2811-C CI brief — competitive landscape report
DA-2811-C updates RSS · CI watch RSS
Dong-A ST Co., Ltd. portfolio CI